M. Lucey

Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1

This study compares the efficacy and affinity of two GLP-1R agonists, P5 and exendin-F1, showing that exendin-F1's lower acute efficacy correlates with sustained insulin secretion and anti-hyperglycaemic effects.

Acylation of the incretin peptide exendin-4 directly impacts GLP-1 receptor signalling and trafficking

This study compares exendin-4 and its acylated variant exendin-4-C16, showing acylation affects GLP-1R signaling bias, trafficking, and pharmacokinetics.

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

This study shows that partial agonism of GLP-1R/GCGR co-agonists improves anti-hyperglycaemic efficacy by reducing β-arrestin-2 recruitment, leading to prolonged glucose-lowering effects and comparable weight loss to liraglutide.

A Universal Stress Protein upregulated by hypoxia may contribute to chronic lung colonisation and intramacrophage survival in cystic fibrosis.

This study identifies distinct roles of two upregulated universal stress proteins in Burkholderia cenocepacia during chronic CF lung infection, showing USP76 supports macrophage survival while USP92 enhances virulence.

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

This study evaluates how C-terminal acylation affects GLP-1R signal bias and in vivo efficacy, finding that acylated ligands show improved therapeutic potential despite reduced potency.

Differences in signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide

This study compares the signalling, trafficking, and glucoregulatory effects of exendin-4 and lixisenatide, finding differences in cAMP signalling potency and receptor recycling that impact glucose control.